These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 25482238)
1. Release the hounds! Activating the T-cell response to cancer. Sznol M; Longo DL N Engl J Med; 2015 Jan; 372(4):374-5. PubMed ID: 25482238 [No Abstract] [Full Text] [Related]
2. Skin cancer. Golden age of melanoma therapy. Hutchinson L Nat Rev Clin Oncol; 2015 Jan; 12(1):1. PubMed ID: 25511188 [No Abstract] [Full Text] [Related]
3. Haematological cancer: PD-1 blockade: opening the door to attack. Hutchinson L Nat Rev Clin Oncol; 2015 Feb; 12(2):65. PubMed ID: 25533946 [No Abstract] [Full Text] [Related]
6. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. Villasboas JC; Ansell SM Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822 [TBL] [Abstract][Full Text] [Related]
9. Skin cancer: less is as good as more in refractory melanoma. Hutchinson L Nat Rev Clin Oncol; 2014 Sep; 11(9):502. PubMed ID: 25091612 [No Abstract] [Full Text] [Related]
10. Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. Gangadhar TC; Schuchter LM JAMA Oncol; 2015 Jul; 1(4):427-8. PubMed ID: 26181246 [No Abstract] [Full Text] [Related]
11. Progress in immunotherapy of cancer. Rook AH; Raphael BA N Engl J Med; 2012 Sep; 367(12):1168; author reply 1168. PubMed ID: 22992095 [No Abstract] [Full Text] [Related]
12. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors. Hamid O Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719 [No Abstract] [Full Text] [Related]
13. Tumor immunotherapy directed at PD-1. Ribas A N Engl J Med; 2012 Jun; 366(26):2517-9. PubMed ID: 22658126 [No Abstract] [Full Text] [Related]
14. PD-1 inhibitors effective in hodgkin lymphoma. Cancer Discov; 2015 Feb; 5(2):102-3. PubMed ID: 25656882 [No Abstract] [Full Text] [Related]
15. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239 [TBL] [Abstract][Full Text] [Related]
16. [Acute myocarditis caused by anti-PD-1 monoclonal antibody in the treatment of refractory Hodgkin lymphoma: a case report]. Shi XL; Wang D; Xu B; Xiao Y Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):424-425. PubMed ID: 32482034 [No Abstract] [Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
18. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Rajan A; Kim C; Heery CR; Guha U; Gulley JL Hum Vaccin Immunother; 2016 Sep; 12(9):2219-31. PubMed ID: 27135835 [TBL] [Abstract][Full Text] [Related]